Close Menu

MGI Tech

BGI will have a chance to depose up to nine inventors of patents assigned to Illumina as part of a lawsuit over IP related to sequencing-by-synthesis chemistry.

A US District Court will prevent BGI from distributing and promoting certain sequencing instruments that allegedly infringe Illumina patents.

Illumina had argued that Complete Genomics' patent covering two-color sequencing-by-synthesis chemistry was obvious, but the US PTAB disagreed.

The researchers said a functional investigation of the virus' unknown transcripts and RNA modifications will elucidate its life cycle and pathogenicity.

Under the terms of the non-exclusive agreement, the companies have made Diagenode's D-Plex library preparation products available on MGI's sequencing platforms.

According to the complaint, the allegedly infringing products include all those that use nucleotides with a 3’-O-azidomethyl blocking group.

At the Advances in Genome Biology and Technology meeting this week, several MGI customers reported results from the DNBSeq-G400.

The DNBSeq Tx system, several of which are already up and running at the China National GeneBank, can churn out up to 100,000 human genomes per year.

BGI is planning to offer free trials of its MGI DNBSEQ-G400 sequencing system to key opinion leaders, a development Illumina is trying to stop.

The court dismissed BGI's counterclaim against Illumina for willful infringement of its patent but allowed the claim for induced infringement to proceed.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.